ACCEL Lite: Optimizing the Care of ASCVD Patients with T2DM

ACCEL Lite: Revascularization of Stable Ischemic Heart Disease in the Era of COURAGE, ISCHEMIA, and ORBITA

ACCEL Lite: Long-Term Secondary Prevention After PCI or MI: Aspirin, Clopidogrel, DAPT or DPI?

ACCEL Lite: Understanding the Basics of HF-rEF and Work Up

ACCEL Lite: ISCHEMIA-EXTENDed – Follow-Up Interim Report

ACCEL Lite: ACC.23 Late-Breaker: Bempedoic Acid and Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular Risk

ACCEL Lite: When Lifestyle Isn't Enough: Surgical vs. Pharmacological Approaches for Obesity

ACCEL Lite: ACC.23 Late-Breaker: Vigorous Exercise in Individuals with Hypertrophic Cardiomyopathy: Primary Results of the LIVE-HCM Study

ACCEL Lite: Statins To Prevent The Cardiotoxicity From Anthracyclines: The STOP-CA Trial

ACCEL Lite: From JACC: CACS Improves Risk Prediction in Patients with Suspected Obstructive CAD

ACCEL Lite: PRECISE – Comparison of a Precision Care Strategy with Usual Testing to Guide Management of Stable Patients With Suspected CAD

ACCEL Lite: IRONMAN – Randomized Trial of Intravenous Ferric Derisomaltose in HFrEF

PROMINENT – A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of CVD

ACCEL Lite: AHA Late-Breaker: PROGRESSIVE-AF – The Impact of “First-Line” Rhythm Therapy on Atrial Fibrillation Progression

AHA Late-Breaker: OCEAN(a)-DOSE – Reduction of Lipoprotein(a) With Small Interfering RNA

AHA Late-Breaker: EMPA-KIDNEY – Empagliflozin and CV Outcomes in Patients with CKD

AHA Late-Breaker: TRANSFORM-HF – Comparative Effectiveness of Torsemide versus Furosemide in Heart Failure: Primary Results

ACCEL Lite: Top Takeaways from 2022: General Cardiology with Glenn Hirsch MD

ACCEL Lite: Top Takeaways from 2022: Preventive Cardiology with Martha Gulati MD

ACCEL Lite: Top Takeaways from 2022: Interventional Cardiology with Dipti Itchhaporia MD